What's in Debiopharm International SA's pipeline?

Debiopharm International SA has 5 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Debiopharm International SA's portfolio?

Top competitors by shared drug class: Clinica Universidad de Navarra, Universidad de Navarra, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Murdoch Childrens Research Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/debiopharm-international-sa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Debiopharm International SA — Portfolio Competitive Intelligence Brief

Debiopharm International SA pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo Tablet or Capsule	Placebo Tablet or Capsule	marketed
Vancomycin IV	Vancomycin IV	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor	Infectious Disease
Debio 4326	Debio 4326	phase 3	Mitochondrial complex I inhibitor	Mitochondrial complex I (NADH dehydrogenase)	Oncology
Debio 4126	Debio 4126	phase 3	Mitochondrial complex I inhibitor	Mitochondrial complex I (NADH dehydrogenase)	Oncology
triptorelin embonate (INN)	triptorelin embonate (INN)	phase 3

Therapeutic area mix

Oncology · 2
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Clinica Universidad de Navarra, Universidad de Navarra · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class
Memorial Sloan Kettering Cancer Center · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Murdoch Childrens Research Institute · 1 shared drug class
OrthoCarolina Research Institute, Inc. · 1 shared drug class
University of Colorado, Denver · 1 shared drug class
University of Maryland, Baltimore · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Debiopharm International SA:

Cite this brief

Drug Landscape (2026). Debiopharm International SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/debiopharm-international-sa. Accessed 2026-05-16.